# Apixaban Evaluation of Interrupted Or Uninterrupted Anticoagulation for Ablation of Atrial Fibrillation

Study · id `cardio:ct-nct02608099` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02608099](<https://clinicaltrials.gov/study/NCT02608099>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02608099

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 300 participants.

## Technical summary

Registry record NCT02608099. Randomized; no masking; primary purpose treatment. Start 2015-11 (registry gives no type); primary completion 2017-04 (actual). Results posted on 2020-03-17.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 300 participants (enrolled count; ClinicalTrials.gov record NCT02608099, source copy `cardio:ctgov-nct02608099-2020-03-17`, retrieved 2026-10-26)
- Start date: 2015-11 (registry gives no type) (ClinicalTrials.gov record NCT02608099, source copy `cardio:ctgov-nct02608099-2020-03-17`, retrieved 2026-10-26)
- Primary completion: 2017-04 (actual) (ClinicalTrials.gov record NCT02608099, source copy `cardio:ctgov-nct02608099-2020-03-17`, retrieved 2026-10-26)
- Completion: 2017-04 (actual) (ClinicalTrials.gov record NCT02608099, source copy `cardio:ctgov-nct02608099-2020-03-17`, retrieved 2026-10-26)
- Results first posted: 2020-03-17 (ClinicalTrials.gov record NCT02608099, source copy `cardio:ctgov-nct02608099-2020-03-17`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT02608099, source copy `cardio:ctgov-nct02608099-2020-03-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02608099-2020-03-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: Apixaban Evaluation of Interrupted Or Uninterrupted Anticoagulation for Ablation of Atrial Fibrillation
- Acronym: AEIOU
- Condition: Atrial Fibrillation
- Intervention (Drug): Interrupted apixaban
- Intervention (Drug): Uninterrupted apixaban
- Lead sponsor: Baim Institute for Clinical Research
- Lead sponsor class: OTHER
- Collaborator: Bristol-Myers Squibb
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Baim Institute for Clinical Research (`cardio:org-baim-institute-for-clinical-research`)
- Registry lists this organization as a collaborator: Bristol-Myers Squibb (`cardio:org-bristol-myers-squibb`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: A Prospective Randomized Trial of Apixaban Dosing During Atrial Fibrillation Ablation: The AEIOU Trial (`cardio:pubmed-29798783`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 7eae9e25902697923b36ffafab009163b0d49db0584bb8b64230682848e70f68
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
